Brilinta

News

Chasing Brilinta payoff, AZ details THALES data in ischemic ...

AstraZeneca has lifted the veil on the large-scale THALES trial of its antiplatelet drug Brilinta in stroke, the company’s last big hope for recouping its substantial investmen

News

FDA grants fast review of AZ's Brilinta to prevent recurring...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring stro

News

AZ claims FDA okay for Brilinta in coronary artery disease p...

AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary a

News